Biocon's Q2 FY 2025-26 Quarterly Results
- 12 Nov 2025
Result Summary
- Biocon Ltd reported a 9.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 21.1%.
- Its expenses for the quarter were up by 7.1% QoQ and 18.4% YoY.
- The net profit increased 48.9% QoQ and increased 390.0% YoY.
- The earnings per share (EPS) of Biocon Ltd stood at 0.65 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 4388.50 | 4021.60 | 3622.90 | 9.1% | 21.1% |
Total Expenses | 4205.30 | 3924.70 | 3550.50 | 7.1% | 18.4% |
Profit Before Tax | 171.30 | 96.90 | 98.40 | 76.8% | 74.1% |
Tax | 38.50 | 7.70 | 71.30 | 400.0% | -46.0% |
Profit After Tax | 132.80 | 89.20 | 27.10 | 48.9% | 390.0% |
Earnings Per Share | 0.65 | 0.26 | -0.13 | 150.0% | -600.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Biocon Ltd is a leading biopharmaceutical company based in India, specializing in the development, manufacturing, and commercialization of biopharmaceuticals. The company operates in the healthcare sector, focusing on innovative and affordable solutions for chronic diseases such as diabetes, cancer, and autoimmune conditions. Biocon’s product portfolio includes biosimilars, novel biologics, and complex generics. The company is known for its strong research and development capabilities and has been involved in several collaborations and strategic partnerships to enhance its product offerings. However, specific recent major developments are not available in the current context.
Revenue
In the second quarter of the fiscal year 2026 (Q2FY26), Biocon Ltd reported a total income of ₹4388.50 crores. This reflects a quarter-over-quarter (QoQ) increase of 9.1% compared to ₹4021.60 crores in the first quarter of FY26 (Q1FY26). Furthermore, the company experienced a significant year-over-year (YoY) growth of 21.1% from ₹3622.90 crores in the second quarter of FY25 (Q2FY25). This substantial growth in total income underscores the company's expansion and enhanced revenue streams over the past year.
Profitability
Biocon Ltd’s profitability saw a remarkable increase in Q2FY26, with the profit before tax (PBT) rising to ₹171.30 crores. This marks a 76.8% QoQ growth from ₹96.90 crores in Q1FY26 and a 74.1% YoY increase from ₹98.40 crores in Q2FY25. The profit after tax (PAT) also showed significant improvement, reaching ₹132.80 crores in Q2FY26. This is a 48.9% increase from ₹89.20 crores in Q1FY26 and an impressive 390.0% rise from ₹27.10 crores in Q2FY25. The company’s tax expense for Q2FY26 was ₹38.50 crores, drastically higher than the ₹7.70 crores in Q1FY26 but lower than the ₹71.30 crores incurred in Q2FY25, reflecting changes in tax liabilities or benefits.
Operating Metrics
Earnings per share (EPS) for Biocon Ltd in Q2FY26 were ₹0.65, representing a notable increase from ₹0.26 in Q1FY26 and a significant improvement from a loss of ₹0.13 in Q2FY25. The YoY change in EPS is a remarkable 600.0%, highlighting the company’s improved earnings capability. Total expenses for Q2FY26 were ₹4205.30 crores, an increase of 7.1% QoQ from ₹3924.70 crores in Q1FY26 and 18.4% YoY from ₹3550.50 crores in Q2FY25. These figures suggest an increase in operational costs aligned with the company’s revenue growth.